Key Highlights

● Shares rose 2.86% to $473.91 pre-market as health-care names gained and tech slid.

● Reported Phase 3 dazodalibep data and a reaffirmed Buy rating remain unconfirmed.

● Peers Gilead, Regeneron, Vertex and Eli Lilly also traded higher in the pre-market session.

● Third-quarter results are due next week, with obesity, Biosimilars and dazodalibep filing in focus.

Amgen (NASDAQ:AMGN) shares were up 2.86% at $473.91 in pre-market trading as of 8:23 a.m. ET Friday, according to a pre-market movers table. The move puts the biotech among a cluster of large health-care names trading higher while technology stocks slide on worries about AI spending.

A quiet gain on a loud morning

An automatically generated news summary for the stock points to three items: a brokerage reaffirming a Buy rating, positive Phase 3 data for dazodalibep, an experimental medicine Amgen is developing for Sjögren's disease, and the company's upcoming third-quarter report, which the summary dates to November 3. The summary cautions that these items may not be the direct cause of a price move, and the details, including the size of any trial benefit and the brokerage's price target, could not be independently confirmed. They should be treated as unverified context.

What can be confirmed is the timing of results. A Friday preview of next week's calendar listed Amgen among more than 100 S&P 500 companies due to report, alongside McDonald's (NYSE:MCD) and ConocoPhillips (NYSE:COP).

Riding the rotation into health care

The broader driver is easier to document. On Thursday, the Health Care Select Sector SPDR fund rose 2.4% and nine of 11 S&P 500 sectors finished higher even as the Nasdaq Composite fell 1.4%, according to market data. In pre-market trading Friday, the health-care fund was up 1.23% while the technology fund was down 3.22%, according to another market tracker.

Amgen's peers are moving the same way. Pre-market data showed Gilead Sciences (NASDAQ:GILD) up 5.30% after raising its 2026 product sales forecast, Regeneron (NASDAQ:REGN) up 6.87% after its quarterly report, Vertex (NASDAQ:VRTX) up 2.60% and Eli Lilly (NYSE:LLY) up 2.78% as of 8:23 a.m. ET. Lilly had jumped 6.4% on Thursday after lifting its full-year Revenue outlook.

Health care, energy, financials and utilities were on track for solid monthly gains in October, according to media reports, while the Nasdaq Composite was down about 2.5% for the month through Thursday. Large drugmakers tend to attract buyers when investors grow uneasy about expensive growth stocks, because their Earnings are less tied to the economic cycle and to the AI capital-spending boom.

What it means for the Dow, the risks and what to watch

Amgen is one of the 30 stocks in the Dow Jones Industrial Average. With a share price in the $470s, it carries a meaningful weight in the price-weighted index, so gains in Amgen and other health-care members help explain why Dow futures were roughly flat early Friday while Nasdaq-100 futures were down about 2.6%, according to market quotes around 8 a.m. ET.

The risks are real. Pre-market gains on thin Volume can fade at the open, and if the rotation reverses toward technology, defensive names could give back ground. Drug pricing remains a policy wildcard: Section 232 pharmaceutical tariffs of up to 100% are in force, though many companies have negotiated deal rates of 15%, and Tuesday's midterm elections could shift the health-care policy outlook. Clinical data also needs full presentation before investors can judge its commercial value.

The next concrete test is Amgen's earnings report next week, where investors will look for updates on its obesity program, biosimilars and the dazodalibep filing path. Before then, Friday's Employment Cost index and Chicago PMI readings will shape the rates backdrop.